Literature DB >> 28328130

Targeted molecular investigation in patients within the clinical spectrum of Auriculocondylar syndrome.

Vanessa L Romanelli Tavares1, Roseli M Zechi-Ceide2, Debora R Bertola1,3, Christopher T Gordon4,5, Simone G Ferreira1, Gabriella S P Hsia1, Guilherme L Yamamoto1,3, Suzana A M Ezquina1, Nancy M Kokitsu-Nakata2, Siulan Vendramini-Pittoli2, Renato S Freitas6, Josiane Souza6, Cesar A Raposo-Amaral7, Mayana Zatz1, Jeanne Amiel4,5,8, Maria L Guion-Almeida2, Maria Rita Passos-Bueno1.   

Abstract

Auriculocondylar syndrome, mainly characterized by micrognathia, small mandibular condyle, and question mark ears, is a rare disease segregating in an autosomal dominant pattern in the majority of the families reported in the literature. So far, pathogenic variants in PLCB4, GNAI3, and EDN1 have been associated with this syndrome. It is caused by a developmental abnormality of the first and second pharyngeal arches and it is associated with great inter- and intra-familial clinical variability, with some patients not presenting the typical phenotype of the syndrome. Moreover, only a few patients of each molecular subtype of Auriculocondylar syndrome have been reported and sequenced. Therefore, the spectrum of clinical and genetic variability is still not defined. In order to address these questions, we searched for alterations in PLCB4, GNAI3, and EDN1 in patients with typical Auriculocondylar syndrome (n = 3), Pierre Robin sequence-plus (n = 3), micrognathia with additional craniofacial malformations (n = 4), or non-specific auricular dysplasia (n = 1), which could represent subtypes of Auriculocondylar syndrome. We found novel pathogenic variants in PLCB4 only in two of three index patients with typical Auriculocondylar syndrome. We also performed a detailed comparative analysis of the patients presented in this study with those previously published, which showed that the pattern of auricular abnormality and full cheeks were associated with molecularly characterized individuals with Auriculocondylar syndrome. Finally, our data contribute to a better definition of a set of parameters for clinical classification that may be used as a guidance for geneticists ordering molecular testing for Auriculocondylar syndrome.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Auriculocondylar syndrome; PLCB4; Pierre Robin sequence; clinical heterogeneity; ear dysplasia; micrognathia; pharyngeal arch; question mark ear

Mesh:

Substances:

Year:  2017        PMID: 28328130     DOI: 10.1002/ajmg.a.38101

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  4 in total

1.  Further phenotypic delineation of the auriculocondylar syndrome type 2 with literature review.

Authors:  Ewelina Bukowska-Olech; Anna Sowińska-Seidler; Filip Łojek; Delfina Popiel; Joanna Walczak-Sztulpa; Aleksander Jamsheer
Journal:  J Appl Genet       Date:  2020-10-31       Impact factor: 3.240

2.  Clinical Profiles and Genetic Spectra of 814 Chinese Children With Short Stature.

Authors:  Xin Li; Ruen Yao; Guoying Chang; Qun Li; Cui Song; Niu Li; Yu Ding; Juan Li; Yao Chen; Yirou Wang; Xiaodong Huang; Yongnian Shen; Hao Zhang; Jian Wang; Xiumin Wang
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

3.  New locus underlying auriculocondylar syndrome (ARCND): 430 kb duplication involving TWIST1 regulatory elements.

Authors:  Vanessa Luiza Romanelli Tavares; Sofia Ligia Guimarães-Ramos; Yan Zhou; Cibele Masotti; Suzana Ezquina; Danielle de Paula Moreira; Henk Buermans; Renato S Freitas; Johan T Den Dunnen; Stephen R F Twigg; Maria Rita Passos-Bueno
Journal:  J Med Genet       Date:  2021-11-08       Impact factor: 5.941

4.  A novel missense variant of the GNAI3 gene and recognisable morphological characteristics of the mandibula in ARCND1.

Authors:  Kumiko Yanagi; Noriko Morimoto; Manami Iso; Yukimi Abe; Kohji Okamura; Tomoo Nakamura; Yoichi Matsubara; Tadashi Kaname
Journal:  J Hum Genet       Date:  2021-03-15       Impact factor: 3.172

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.